LIXTE Biotechnology Holdings is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event scheduled for February 19 at Morehouse College in Atlanta. The summit, inspired by the music and legacy of De La Soul, brings together leaders in health, culture, science, and community to advance health equity for Black men and families. Developed in collaboration with Blacksmith holdings, the program reflects De La Soul's evolution from musical pioneers to wellness advocates and will feature discussions spanning cancer, heart disease, mental health, addiction, sleep, relationships, and intergenerational wellness.
The company stated that the summit aligns with its mission as a clinical-stage pharmaceutical company advancing cancer care through its first-in-class oncology compound LB-100 and its European research subsidiary, LIORA. LIXTE is creating a space to connect scientific innovation with communities most impacted by health disparities. The event is rooted in De La Soul's song "Good Health," written following the passing of founding member David Jolicoeur.
LIXTE Biotechnology Holdings is focused on new targets for cancer drug development and developing and commercializing cancer therapies. The company has demonstrated that its lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data available at https://www.lixte.com, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
LIXTE's lead compound represents a pioneering effort in an entirely new field of cancer biology called activation lethality, advancing a new treatment paradigm covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company's sponsorship of the health summit represents a strategic alignment between pharmaceutical innovation and community health initiatives, particularly addressing health disparities that disproportionately affect Black communities.
For business and technology leaders, this partnership demonstrates how pharmaceutical companies are expanding their engagement beyond traditional research and development to address systemic health inequities. The intersection of scientific advancement and community health represents a growing trend in the healthcare industry, where companies recognize that improving health outcomes requires both innovative treatments and addressing social determinants of health. The summit's focus on multiple health dimensions—from cancer and heart disease to mental health and relationships—reflects a holistic approach to wellness that aligns with broader healthcare trends toward integrated care models.
The collaboration between a biotechnology firm and cultural influencers like De La Soul represents an innovative approach to health communication and community engagement. By leveraging cultural relevance and trusted community voices, such initiatives may improve health literacy and access to care in underserved populations. For leaders in business and technology, this model offers insights into how corporate social responsibility initiatives can be strategically aligned with core business objectives while addressing pressing social challenges.
Forward-looking statements in the press release involve risks and uncertainties that may cause actual results to differ materially from expressed expectations. These statements are subject to various factors beyond management's control, including risks discussed in the company's SEC filings. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
